David, In answer to your question about the new OPS member forum and Optimal, the answer is no, it is not intended to replace Optimal. They are two different vehicles with different audiences. Optimal has never been an official OPS discussion group. It was started and maintained by Joe Warnicki and Paul Montague purposely separate from the OPS, even though many people mistakenly assocate Optimal with the OPS. Joe continues to graciously maintain Optimal as an open forum for anyone with an interest in ophthalmic imaging. Optimal has a "flavor" of comraderie that's developed over many years and my guess is that's unlikely to change. The new OPS forum is visible to anyone visting the OPS website, but participation (posting) is limited to OPS members who are signed in to the site. It is being offered as a benefit to our members. We (the OPS) don't want to compete with Optimal and believe there is room for both forums. In fact there is now a third forum for ophthalmic imagers: the OPS fan page on Facebook. That has a different flavor that will likely reach a different audience as well. Hope this helps, tim Timothy J. Bennett, CRA, FOPS, OCT-C Penn State Department of Ophthalmology Milton S. Hershey Medical Center 500 University Drive, Suite 800 UPC Hershey, PA 17033 Office: 717 531-5516 Cell: 717 381-5595 From: optimal-bounce@xxxxxxxxxxxxx [mailto:optimal-bounce@xxxxxxxxxxxxx] On Behalf Of David Cimino Sent: Thursday, March 01, 2012 5:12 PM To: optimal@xxxxxxxxxxxxx Subject: [optimal] Treating POHS with Avastin Does anyone know of any papers published on treating POHS with Avastin? A Google search proved useless. And BTW, the new material and content on the site looks GREAT! Will Optimal be replaced with the new forum? Thanks, David David Cimino, CRA COA Southeastern Retina Associates This E-mail message, including any attachments, is for the sole use of the intended recipients and may contain privileged and/or confidential or otherwise protected information. It is not intended for transmission to or receipt by any unauthorized persons. Any unauthorized review, use, disclosure or distribution is prohibited. If you have received this communication in error, please notify the sender by reply transmission and delete the message without copying or disclosing it.